Author of Nature Paper Questioning Opko Data Responds to Criticism from Company

Jayakrishna Ambati, who co-authored last week’s Nature paper showing how siRNAs suppress neovascularization regardless of their sequences or targets, defended his data as reproducible. He also questioned the validity of claims made by an Opko Health official about the company’s phase III AMD drug bevasiranib.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.